0512-67998889(Suzhou)
18051093220(Shenzhen)
On September 6, 2023, a distinguished group of leaders and specialists from entities such as Guozhu Capital—a subsidiary of Qingdao Ronghui Investment Holding Group—Qingdao's Shibei District Development and Reform Bureau, Shandong Port Medical and Nursing Health Management Group, Doshi Capital, and the Riemann Hypothesis, visited RocRock Biotechnology (Suzhou) Co., Ltd. to explore collaborative opportunities for regional growth and investment partnerships. The visit was hosted by key figures including Mr. Xiao Shitao, who holds the positions of Chairman of the Science and Technology Association, Deputy Director of the Science and Innovation Committee, and Director of the Science and Technology Recruitment Center at the Suzhou Industrial Park Management Committee, Ms. Yu Liyan, Deputy Director of the Science and Technology Recruitment Center, and Mr. Yin Xiushan, CEO of RocRock Biotechnology.
（Group photo）
RocRock Biotechnology, in collaboration with the Suzhou Industrial Park Management Committee, extended a grand welcome to the visiting officials from the Qingdao Shibei District Government. The delegation commenced their visit with a tour of the Suzhou Industrial Park Exhibition Center, where they delved into the park's evolution, its strategic industrial distribution, and the cutting-edge research and development in the biopharmaceutical sector. Throughout the tour, there was an exploration of strategies to harness the capabilities of the National Biomedical Innovation Center, with the aim of enhancing the collaborative growth of the biopharmaceutical sectors in both Suzhou Industrial Park and Qingdao's Shibei District. The focus was on catalyzing advancements in technology and spurring industrial evolution through such synergistic regional development.
（Group photo ）
In the collaborative discussion phase, representatives from Qingdao's Shibei District and the Suzhou Industrial Park Management Committee explored investment cooperation opportunities and future strategies concerning the market potential, technical hurdles, therapeutic outcomes, and policy backing of RocRock Biotechnology's CAR-M cellular therapy. They engaged in profound dialogue and weighed viable implementation strategies for the macrophage pharmaceutical development initiative. Looking ahead, the government of Qingdao's Shibei District and Kunshi Biotechnology are set to enhance their partnership to drive advancements in biomedicine, foster innovation in solid tumor treatments, offer patients more potent treatment options, and stimulate advancements in medical technology. During the seminar, Director Xiao commended RocRock's innovative and entrepreneurial prowess, while Director Yu emphasized the park management committee's role as a collaborative partner, bearing significant responsibilities to nurture business growth and development. The general manager of Guozhu Capital remarked that Qingdao's Shibei District intends to emulate Suzhou Industrial Park's developmental triumphs, charting a sustainable trajectory tailored to their district's needs.
Yin Xiushan, founder of RocRock Biotechnology, stated with pride that as the sole entity in China wholly committed to macrophage treatments, RocRock is privileged to join forces with Qingdao's Shibei District Government and the Suzhou Industrial Park Management Committee on this project. The collective goal is to expedite the commercialization of cellular medicines and outpace the United States in this domain
（Meeting and negotiation ）
A key event of the research visit was the inspection of the B+A cell production and preparation lab, the nation's first dedicated to macrophage therapy. This visit provided insights into RocRock Biotechnology's lab setup, cell and viral manufacturing workflows, four major technological platforms, and quality management systems. Guozhu Capital and the Qingdao Shibei District Development and Reform Bureau commended RocRock's progress in CAR-M cell therapy and proposed constructive feedback for future scientific endeavors. CAR-M therapy, at the forefront of biomedicine, signifies the newest outcomes of scientific and medical innovation, holding significant potential to enhance global quality of life. This technology is set to impact not only the treatment of various cancers but also extend to immune and chronic diseases in the future. RocRock's founder, Yin Xiushan, a native of Shandong, declared that RocRock's new entity, pivotal in macrophage production and formulation, will be firmly rooted in Qingdao, with ambitions to lead globally in macrophage cell production and services. This initiative aims to bolster Shandong's biotech sector, contributing to the region's economic and technological growth.
（ Visit the laboratory）
The visit has solidified the collaborative intentions between the Qingdao Shibei District Government and RocRock Biotechnology, underscoring the district government's commitment to advancing in the biopharmaceutical sector. This partnership, spanning different regions and fields, will optimize the use of each party's advantages and resources, leading to a mutually beneficial outcome. It is set to establish more advantageous conditions for the development and application of CAR-M therapies, promising an influx of innovative achievements and breakthroughs in the realm of medical science.
About Qingdao Guozhu Asset Management Co., LTD
IN REGARD TO
Guozhu Capital, a subsidiary of Qingdao Guozhu Asset Management Co., Ltd., operates with a dual approach of state guidance and market-driven strategies across three main business areas: equity investment, asset management, and industrial financial services. The company concentrates its investments in the realms of technological and medical innovation, leveraging a network of mother funds to amplify and refine its industrial investments. It actively broadens its cooperative partnerships, channeling a variety of high-quality collaborative resources into Qingdao's Shibei District. This effort not only enhances the operational capabilities and profitability of state-owned capital but also fosters mutual growth. In alignment with Shibei District's strategic blueprint, Guozhu Capital targets the "two belts and three districts" development framework and the "2+6" distinctive industry system. It employs capital to drive industry upgrades and attract new industries, fully committed to establishing the "Qingdao Huizhu New Shibei Billion-Yuan Industrial Development Mother Fund Group." This initiative is designed to bolster the transformation of Shibei District into a flourishing, attractive, and contented modern international urban area, contributing financial might to Qingdao's urban development.
About Shandong Port Medical Care Health Management Group Co., LTD
IN REGARD TO
Shandong Port Medical and Nursing Health Management Group Co., Ltd., a state-owned conglomerate under the Shandong Port Group, encompasses a spectrum of medical and health services including healthcare, rehabilitation, health management, and geriatric care. The group boasts brands such as the Qingdao Fuwai Cardiovascular and Thoracic Hospital—a tier-3 specialty institution—alongside the Rizhao Port Hospital and Yantai Haigang Hospital, both tier-2 general facilities. They operate over 1800 beds, employ more than 360 senior professional technicians, and maintain specialized departments in cardiovascular care, rehabilitation, orthopedics, urology, general surgery, neurology, ophthalmology, and health management. The group handles a substantial annual caseload of 1 million outpatient and emergency visits, 50,000 patient discharges, and executes 30,000 surgical procedures. As a pioneer in harbor-focused medical and geriatric health, the company is dedicated to a healthcare-centric approach, bolstered by health management and oriented towards geriatric care, setting a benchmark for the industry.
0512-67998889(Suzhou)
18051093220(Shenzhen)
Cathy.Lv@rocrockbio.com(Suzhou)
lliangjing@rocrockbio.com (Shenzhen)